Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Kidney and Transplant

No studies found 0 · 0%GRADE not reported 1 · 14.3%Very low 1 · 14.3%Low 1 · 14.3%Moderate 4 · 57.1%High 0 · 0%

Any nephrotoxicity ‐ Ag dosing regimen (Copy) · patients with proven or suspected infection

Teicoplanin probably leads to lower nephrotoxicity compared with vancomycin (moderate certainty).

1 finding from 1 review

Teicoplanin versus vancomycin for proven or suspected infection 2010 · Cochrane Headline outcomes only
RR 0.66 [0.48, 0.9]
23 studies · 2596 participants
Moderate

Clinical efficacy ‐ cure or improvement at · patients with proven or suspected infection

Teicoplanin showed no clear difference in clinical cure or improvement compared with vancomycin (moderate certainty).

1 finding from 1 review

Teicoplanin versus vancomycin for proven or suspected infection 2010 · Cochrane Headline outcomes only
RR 1.03 [0.98, 1.08]
20 studies · 1703 participants
Moderate

Microbiological cure · patients with proven or suspected infection

Teicoplanin showed no clear difference in microbiological cure compared with vancomycin (moderate certainty).

1 finding from 1 review

Teicoplanin versus vancomycin for proven or suspected infection 2010 · Cochrane Headline outcomes only
RR 0.98 [0.93, 1.03]
16 studies · 914 participants
Moderate

Renal failure needing dialysis2 · patients with proven or suspected infection

1 finding from 1 review

Teicoplanin versus vancomycin for proven or suspected infection 2010 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 606 participants
GRADE not reported

All‐cause mortality · patients with proven or suspected infection

Teicoplanin showed no clear difference in mortality compared with vancomycin (low certainty).

1 finding from 1 review

Teicoplanin versus vancomycin for proven or suspected infection 2010 · Cochrane Headline outcomes only
RR 1.02 [0.79, 1.3]
16 studies · 1565 participants
Low

Rash · patients with proven or suspected infection

Teicoplanin probably leads to lower cutaneous rash compared with vancomycin (moderate certainty).

1 finding from 1 review

Teicoplanin versus vancomycin for proven or suspected infection 2010 · Cochrane Headline outcomes only
RR 0.57 [0.35, 0.92]
18 studies · 1823 participants
Moderate

Total adverse events · patients with proven or suspected infection

It is very uncertain whether teicoplanin changes total adverse events compared with vancomycin (very low certainty).

1 finding from 1 review

Teicoplanin versus vancomycin for proven or suspected infection 2010 · Cochrane Headline outcomes only
RR 0.56 [0.33, 0.95]
11 studies · 880 participants
Very low